Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



# 中關村科技租賃股份有限公司 ZHONGGUANCUN SCIENCE-TECH LEASING CO., LTD.

 $(a\ joint\ stock\ company\ incorporated\ in\ the\ People's\ Republic\ of\ China\ with\ limited\ liability)$ 

(Stock Code: 1601)

# DISCLOSEABLE TRANSACTION FINANCE LEASE TRANSACTION

# FINANCE LEASE AGREEMENT

The Board hereby announces that on November 30, 2023, the Company (as the Lessor) entered into the Finance Lease Agreement with the Lessee, pursuant to which, (i) the Lessor shall acquire the Leased Assets owned by the Lessee at a transfer consideration of RMB44,000,000; and (ii) the Lessor shall lease the Leased Assets back to the Lessee for a term of 36 months with a total lease payment of RMB48,481,085, which shall include a finance lease principal of RMB44,000,000 and a finance lease interest income (inclusive of VAT) of RMB4,481,085.

# LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio of the Financial Lease Agreement is higher than 5% but less than 25%, the transaction contemplated under the Finance Lease Agreement constitutes a discloseable transaction of the Company and are subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

# **BACKGROUND**

The Board hereby announces that on November 30, 2023, the Company (as the Lessor) entered into the Finance Lease Agreement with the Lessee, pursuant to which, (i) the Lessor shall acquire the Leased Assets owned by the Lessee at a transfer consideration of RMB44,000,000; and (ii) the Lessor shall lease the Leased Assets back to the Lessee for a term of 36 months with a total lease payment of RMB48,481,085, which shall include a finance lease principal of RMB44,000,000 and a finance lease interest income (inclusive of VAT) of RMB4,481,085.

# THE FINANCE LEASE AGREEMENT

The principal terms of the Finance Lease Agreement are as follows:

# **Parties**

Lessor: the Company

Lessee: a limited liability company incorporated in the PRC, which is principally engaged in

the research and development, production, and sales of vaccines.

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, the Lessee and its ultimate beneficial owner are all independent third parties to the Company and its connected persons (as defined in the Listing Rules).

#### **Leased Assets**

The Leased Assets are production equipment related to human vaccinest, with a net book value of approximately RMB46,820,622.20.

The Lessee does not separately calculate the profits before and after tax of the Leased Assets. The transfer consideration for the acquisition of the Leased Assets under the Finance Lease Agreement will be funded by the Company's internal resources. If the Lessee has properly and fully performed all of its obligations under the Finance Lease Agreement, the Lessee is entitled to acquire the Leased Assets at the consideration of RMB100 in nominal value pursuant to the terms and conditions of the Finance Lease Agreement, upon the expiry of the Finance Lease Agreement.

# **Lease Period**

The lease period of the Finance Lease Agreement is 36 months, which shall commence on November 30, 2023.

# **Lease Payment and Method of Payment**

Under the Finance Lease Agreement, the total lease payment of RMB48,481,085 included the finance lease principal of RMB44,000,000 and the finance lease interest income (inclusive of VAT) of RMB4,481,085 (calculated based on the interest rate of 6.2% per annum). The Lessee shall pay the lease payment to the Lessor at the end of each quarter in installments in accordance with the terms and conditions of the Finance Lease Agreement during the lease period.

The terms of the Finance Lease Agreement, including the transfer consideration for the Leased Assets, finance lease principal, finance lease interest income and other expenses, were determined upon arm's length negotiation between the Lessee and the Lessor with reference to net book value of the Leased Assets and prevailing market prices of the same category of finance lease products in the PRC.

# **Security Deposit**

The Lessee agreed to pay the security deposit for the Finance Lease Agreement of RMB4,000,000 (bearing nil interests). When the last lease payment is due to be paid, the lease payment and other payables under the final payment will automatically be deducted from the deposit, and the Lessor will refund the Lessee the remaining amount (if any).

#### **Guarantee and Security**

The guarantee and security arrangements for the Finance Lease Agreement are set out below:

- (1) The ultimate beneficial owner of the Lessee shall provide joint and several liabilities guarantee for the debts of Lessee under the Finance Lease Agreement.
- (2) The Lessee shall provide land mortgage.

# REASONS FOR AND BENEFITS OF ENTERING INTO THE FINANCE LEASE AGREEMENT

The Company's principal activities are to provide finance leasing and advisory services to customers. The entering of the Finance Lease Agreement is part of the Company's ordinary and usual course of business, which is expected to provide a stable revenue and cashflow to the Company.

The Directors consider that entering into the Finance Lease Agreement will generate revenue and profit to the Company over the lease period and is consistent with the Company's business development strategy. Since the Finance Lease Agreement was entered into under normal commercial terms, the Directors are of the view that the terms under the Finance Lease Agreement are fair and reasonable and are in the interests of the Company and its shareholders as a whole.

# INFORMATION OF THE PARTIES

# **Information of the Company**

The Company is a pioneer and a dedicated finance lease company in serving technology and new economy companies in China. As the sole finance lease platform under Zhongguancun Development Group Co., Ltd. (中關村發展集團股份有限公司), the Company offers efficient finance lease solutions and a variety of advisory services to satisfy technology and new economy companies' needs for financial services at different stages of their growth. The Company's finance lease solutions primarily take the form of direct lease and sale-and-leaseback. The Company also delivers a variety of advisory services, including policy advisory and management and business consulting, to help its customers achieve rapid growth.

#### **Information of the Lessee**

Lessee is a limited liability company incorporated in the PRC, which is principally engaged in the research and development, production, and sales of vaccines.

# LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio of the Financial Lease Agreement is higher than 5% but less than 25%, the transaction contemplated under the Finance Lease Agreement constitutes a discloseable transaction of the Company and are subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

# **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following terms have the following meanings:

"Board" the board of directors of the Company

"Company" Zhongguancun Science-Tech Leasing Co., Ltd. (中關村科技租賃

股份有限公司), a joint stock company incorporated under the laws of the PRC with limited liability, the H shares of which are listed on

the Stock Exchange with stock code of 1601

"Director(s)" the director(s) of the Company

"Finance Lease Agreement" the finance lease agreement entered into between the Lessor and

Lessee on November 30, 2023

"independent third party(ies)" any individual or company not being the connected persons (as

defined under the Listing Rules) of the Company, independent of the Company and its connected persons (as defined under the Listing

Rules) and not connected with them

"Leased Assets" production equipment related to human vaccines, with a net book

value of approximately RMB46,820,622.20

"Lessee" Zhongyi Anke Biotechnology Co., Ltd \* (中 逸 安 科 生 物 技 術

股份有限公司), a limited liability company incorporated in the PRC, which is principally engaged in the research and development, production, and sales of vaccines. The ultimate beneficial owner of the

Lessee is Gao Hui \* (高輝)

"Lessor" the Company

"Listing Rules" the Rules Governing the Listing of Securities on The Stock Exchange

of Hong Kong Limited

"PRC" or "China" the People's Republic of China, which, for the purpose of this

announcement, excludes the Hong Kong Special Administrative Region of the PRC, the Macau Special Administrative Region of the

PRC and Taiwan

"RMB" Renminbi, the lawful currency of the PRC

"Stock Exchange" The Stock Exchange of Hong Kong Limited

"VAT" value-added tax

By order of the Board

Zhongguancun Science-Tech Leasing Co., Ltd.

ZHANG Shuqing

Chairman

Beijing, the PRC, November 30, 2023

As at the date of this announcement, the Board comprises Mr. HE Rongfeng and Mr. HUANG Wen as executive Directors, Mr. ZHANG Shuqing, Mr. LOU Yixiang and Ms. WANG Sujuan as non-executive Directors, and Mr. CHENG Dongyue, Mr. WU Tak Lung and Ms. LIN Zhen as independent non-executive Directors.

\* For identification purposes only.